Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit
proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been …

The c-Jun N-terminal kinases (JNKs), as members of the mitogen-activated protein kinase
(MAPK) family, mediate eukaryotic cell responses to a wide range of abiotic and biotic stress …

Purpose Advanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung
cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs) …

One strategy for combating cancer-drug resistance is to deploy rational polytherapy up front
that suppresses the survival and emergence of resistant tumor cells. Here we demonstrate in …

The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as
a component of the fusion protein nucleophosmin (NPM)–ALK in anaplastic large-cell …

Since the discovery of the fusion between EML4 (echinoderm microtubule associated
protein-like 4) and ALK (anaplastic lymphoma kinase), EML4-ALK, in lung adenocarcinomas …

Background Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the
standard of care in advancedALK-rearranged non-small cell lung cancer (NSCLC), but the …

Since the discovery of echinoderm microtubule-associated protein-like 4 (EML4) and
anaplastic lymphoma kinase (ALK) gene fusion in non-small cell lung carcinoma (NSCLC) …

Non‑small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality
rate that is a threat to human health. With the development of molecular targeted research …

Anaplastic lymphoma kinase (ALK) can be driven to oncogenic activity by different types of
mutational events such as point‐mutations, for example F1174L in neuroblastoma, and …